Volume | 15,551 |
|
|||||
News | - | ||||||
Day High | 4.55 | Low High |
|||||
Day Low | 4.19 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.33 | 4.19 | 4.55 | 4.335 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
204 | 15,551 | $ 4.36 | $ 67,863 | - | 0.6706 - 9.6799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:31:38 | 2 | $ 4.28 | USD |
Marker Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
39.02M | 8.89M | - | 9.01M | -29.93M | -3.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Marker Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.52 | 4.91 | 4.1101 | 4.53 | 22,668 | -0.14 | -3.10% |
1 Month | 3.68 | 4.91 | 3.40 | 4.22 | 21,253 | 0.70 | 19.02% |
3 Months | 5.29 | 5.41 | 3.40 | 4.35 | 20,122 | -0.91 | -17.20% |
6 Months | 4.70 | 6.1568 | 2.40 | 4.37 | 52,257 | -0.32 | -6.81% |
1 Year | 0.802 | 9.6799 | 0.6706 | 2.59 | 273,719 | 3.58 | 446.13% |
3 Years | 23.40 | 36.50 | 0.6706 | 11.39 | 612,843 | -19.02 | -81.28% |
5 Years | 67.50 | 91.70 | 0.6706 | 20.18 | 665,874 | -63.12 | -93.51% |
Marker Therapeutics Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |